Mechanisms and management of doxorubicin cardiotoxicity (Q38473474)

3 September 2017

Mechanisms and management of doxorubicin cardiotoxicity (English)

1 reference

3 September 2017

1 reference

Y Shi

1

1 reference

3 September 2017

M Moon

2

1 reference

3 September 2017

S Dawood

3

1 reference

3 September 2017

B McManus

4

1 reference

3 September 2017

P P Liu

5

1 reference

3 September 2017

1 June 2011

1 reference

3 September 2017

1 reference

3 September 2017

36

1 reference

3 September 2017

4

1 reference

3 September 2017

296-305

1 reference

DNA topoisomerases and their poisoning by anticancer and antibacterial drugs

3 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Differences in accumulation of anthracyclines daunorubicin, doxorubicin and epirubicin in rat tissues revealed by immunocytochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Transcriptional analysis of doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Cardiomyocyte death in doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Role of mtDNA lesions in anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

DNA damage is an early event in doxorubicin-induced cardiac myocyte death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin-induced cardiac mitochondrionopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Mechanism of anthracycline-mediated down-regulation of GATA4 in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Expression of p300 protects cardiac myocytes from apoptosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

CREB-binding protein and p300 in transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Autophagy in cardiac myocyte homeostasis, aging, and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The involvement of lysosomes in myocardial aging and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Oxidative stress and apoptosis in heart dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The telomere-telomerase axis and the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The aging cardiomyocyte: a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Protein quality control and degradation in cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Activation of the ubiquitin-proteasome system in doxorubicin cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Heart failure and protein quality control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The bitter end: the ubiquitin-proteasome system and cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Structure and function of the yeast U-box-containing ubiquitin ligase Ufd2p

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The ubiquitin-proteasome system in cardiac physiology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Degradation of oxidized proteins by the 20S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

p53 initiates apoptosis by transcriptionally targeting the antiapoptotic protein ARC

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The apoptosis inhibitor ARC undergoes ubiquitin-proteasomal-mediated degradation in response to death stimuli: identification of a degradation-resistant mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

GPx-1 gene delivery modulates NFkappaB activation following diverse environmental injuries through a specific subunit of the IKK complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Hypertrophy and atrophy of the heart: the other side of remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Identification of ubiquitin ligases required for skeletal muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Involvement of transcriptional factor TonEBP in the regulation of the taurine transporter in the cardiomyocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Multiple novel transcription initiation sites for NRG1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

The EGF receptor family: spearheading a merger of signaling and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

ErbB receptors: new insights on mechanisms and biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Mechanisms of Myocardial Regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Cardiac progenitor cells: potency and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Adriamycin nephropathy: a failure of endothelial progenitor cell-induced repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Angiopoietin-1 inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating fas expression and via the PI3K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Cardiotoxicity of anticancer treatments: what the cardiologist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Anthracycline associated cardiotoxicity in survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Beneficial effect of taurine treatment against doxorubicin-induced cardiotoxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Vincristine attenuates doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Adiponectin protects against doxorubicin-induced cardiomyopathy by anti-apoptotic effects through AMPK up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Critical role of nuclear calcium/calmodulin-dependent protein kinase IIdeltaB in cardiomyocyte survival in cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00059-011-3470-3

Degradation of NFAT5, a transcriptional regulator of osmotic stress-related genes, is a critical event for doxorubicin-induced cytotoxicity in cardiac myocytes

21 January 2018

1 reference

12 December 2020

Adriamycin-induced modulation of host defenses in tumor-bearing mice

1 reference

12 December 2020

L-carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes

1 reference

12 December 2020

Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function

1 reference

12 December 2020

Zinc inhibits doxorubicin-activated calcineurin signal transduction pathway in H9c2 embryonic rat cardiac cells.

1 reference

12 December 2020

Pharmacokinetics and metabolism of anthracyclines

1 reference

12 December 2020

TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin.

1 reference

12 December 2020

Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes

1 reference

12 December 2020

Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas

1 reference

12 December 2020

Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis

1 reference

12 December 2020

Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture

1 reference

12 December 2020

Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin

1 reference

12 December 2020

Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy

1 reference

12 December 2020

Molecular pharmacology of the interaction of anthracyclines with iron

1 reference

12 December 2020

The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction

1 reference

12 December 2020

Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes

1 reference

12 December 2020

Innate immunity in the adult mammalian heart: for whom the cell tolls.

1 reference

12 December 2020

Function for p300 and not CBP in the apoptotic response to DNA damage

1 reference

12 December 2020

Cardiotoxicity of antitumor drugs

1 reference

12 December 2020

Molecular biology of doxorubicin-induced cardiomyopathy

1 reference

12 December 2020

Doxorubicin degradation in cardiomyocytes

1 reference

12 December 2020

Length dependence of tension generation in rat skinned cardiac muscle: role of titin in the Frank-Starling mechanism of the heart

1 reference

12 December 2020

Adriamycin-activated macrophages as tumor growth inhibitors

1 reference

12 December 2020

Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity

1 reference

12 December 2020

Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits

1 reference

12 December 2020

10.1007/S00059-011-3470-3

Identifiers

DOI

1 reference

3 September 2017

1 reference